Nanosonics Limited (NAN) Earnings Call Transcript
August 26, 2025
Earnings Call Speaker Segments
Thank you so much, Catherine, and good morning to everyone. I appreciate all of you taking the time to be on this call. You'll have seen the full-year results for FY 2025 by this point, and I believe they reflect a really strong set of financial and operational achievements for the year. Before we dive into the specifics, I'd like to highlight a few important points. The first is the 17% revenue growth we delivered this year. That really underscores the strength and scalability of our trophon business model, in which the substantial and expanding installed base we've built up by now is fueling faster growth in recurring revenue through our strategies for customer value and expansion. Naturally, this also underpinned robust bottom-line growth and operating leverage for the year. The second is that we anticipate multiple growth drivers for trophon going forward, and I'll touch on some of those a little later. As the trophon-only financials in the presentations show, the trophon business is highly profitable. It produces very strong cash flow, and along with our already solid cash position, that clearly gives us the ability to invest in our next growth horizon. Third, and importantly, we reached a number of key strategic milestones during the year spanning innovation, operations, and digitalization.
Every one of these milestones matters for the growth phase we're entering next, and I'll touch on a number of them briefly as well. Last, CORIS hit a lot of significant milestones over the year, and the following steps in our commercialization plans are at this point quite clearly laid out and, in fact, already in motion. Taking the results in somewhat finer detail, beginning with a few of the financial highlights, which Jason will soon go into further, revenue rose 17% for the year to AUD 198.6 million. That landed squarely at the upper end of the upgraded guidance we gave at the half year. Our installed base was up 6%, with the cumulative installed base having now hit 37,000 trophon units. This big and expanding critical mass of installed devices helped drive 20% growth in recurring revenue from consumables and service, reaching AUD 146.1 million for the year. Total unit sales came to 3,870 units, of which 2,210 were new installed base and 1,660 were upgrades. Combined, those produced a 9% rise in capital revenue to AUD 52.5 million. Gross profit margin improved to 78.2%. Disciplined growth across our operating expenses, which rose 10% for the year, delivered a great many of the key milestones for our future growth.
What's important is that we clearly saw better operating leverage, with OpEx falling as a share of revenue. That fed through to substantial profit growth: profit before tax rose 72% to AUD 22.3 million. As I noted, we hit a number of key milestones this year, and each one lays the groundwork for the growth phase ahead. On the innovation side, we obtained FDA clearance for CORIS. We finished development of our next-generation trophon technology, which let us launch trophon3 and trophon2 Plus just recently. Our patent portfolio also grew as we keep advancing our product roadmaps and expanding the portfolio. On the operational side, our progress has been considerable. We've stood up the CORIS supply chain and established manufacturing for CORIS equipment production here in Sydney. We also enlarged our Indianapolis facility in the U.S. so it can make consumables for both trophon and CORIS, and we secured the required regulatory approvals and registrations for that site. Those production lines should go live later this year. At Indianapolis, we further broadened the servicing capability at the facility to back the growth we're seeing in our service business. When it comes to digitalization, we accomplished a great deal this year, successfully implementing a new ERP system.
That's going to underpin the business going forward and act as an enabler for several of our productivity initiatives. Also important, we set up our cloud infrastructure to enable wider connectivity for customers and future revenue of the SaaS type. With the recent releases of trophon3 and trophon2 Plus, cloud-based traceability features are included, and all of this adds value for our customers. In line with our broader digital strategy, we strengthened our cybersecurity position further, achieving ISO 27001 recertification at a higher standard. We already have plans in place ahead of time for additional enhancements and international accreditations. These significant milestones, together with numerous other operational accomplishments, have truly laid crucial foundations for our next growth horizon. Before I continue, although it isn't shown on the actual slide, I'd also like to note a few of our sustainability achievements over the year. Electricity usage has historically been the main driver of our Scope 2 emissions. Sourcing 100% renewable energy for use across both our Australian and U.S. business operations has been a key element of our carbon reduction strategy. In FY 2025 we fulfilled that commitment. Consequently, roughly 56%, or 270 tons, of our Scope 2 emissions have been abated. In addition, our Scope 1 emissions fell by approximately 17% over the year.
We anticipate those will drop even more in FY 2026 as the full-year benefit comes through. Naturally, we'll keep looking for additional areas where we can shrink our overall footprint, which isn't large to begin with. Turning to recurring revenue growth, which stood out this year and rose 20% on the back of 6% growth in cumulative installed base — beyond the benefit for the 28 million patients protected annually from the risk of cross-contamination, this large and expanding installed base is fueling scalable recurring revenue growth, with room to keep delivering further value for our customers. Breaking that recurring revenue down, it includes a number of product categories. Importantly, we saw strong growth across each of them. First, we have revenue from core consumables and spare parts. Those consumables are the ones used in the disinfection itself. This was up 18%, and that was mainly driven by volume growth to AUD 101.7 million. There was a little bit of price in there, but it was mainly driven by volume growth. Likewise, revenue from our ecosystem consumables — and those consumables include products like wipes and clean covers — was actually up 28% to AUD 15.1 million.
Our services segment kept up its strong momentum, rising once more by 21% over the year to AUD 29.4 million. In total, that meant AUD 146.1 million of recurring revenue delivered. What matters is that every piece of that revenue carries genuinely solid headroom for further expansion. And on this recurring revenue, we anticipate adding one more significant element going forward. Through the launch of trophon3 and trophon2 Plus, connectivity with customers' DICOM imaging systems is now available. That gives complete digital traceability tied to patient records. DICOM serves as the worldwide standard for medical imaging data. This integration puts us in a good position for SaaS-style revenue down the road. Going forward, digital revenue is clearly something we view as a key part of expanding customer value, which naturally fuels growth in our recurring revenue. On the whole, we're highly satisfied — not only with the financial growth itself, but with how good that growth is and the possibilities it opens up, which I'll get to shortly. Ahead of that, I'll pass things to Jason so he can take everyone through the financials in greater detail. Jason.
Thanks, Michael, and good morning, everyone. Before I walk you through the financials, I want to take a moment to highlight a few of the key financial messages that show how Nanosonics is driving value creation. First, we've built a trusted brand in automated high-level disinfection, with more than 37,000 trophons installed at present. That broad installed base drives our high-margin recurring revenue, demonstrating the strength of our business model. Our disciplined capital allocation has delivered operating leverage improvements and EBIT growth in the 2025 financial year, which reflects our commitment to financial prudence and to strategic investments for growth. This approach has produced strong cash generation and high returns on capital in the trophon-only business, giving us flexibility to invest in future growth opportunities. As we keep growing our trophon business and begin to commercialize CORIS, we're well positioned to capture new market opportunities and deliver sustained value to our shareholders. Turning to our P&L, it shows significant improvement year-on-year. We've been able to pair strong revenue growth with measured increases in operating expenses. As Michael already mentioned, total revenue grew 17%, reaching AUD 198.6 million. I'm pleased to report that we have achieved revenue growth across all regions, with North America growing 17%, EMEA 22%, and APAC 4%.
Margin got better too, and I’ll return to that in a moment. Our operating expenses rose 10%, reaching AUD 138.7 million. Within operating expenses, we reported 6% growth in R&D investment. It’s worth noting that R&D fell as a share of revenue, from 19% to 17% in FY 2025, and we expect that trend to continue. I’ll also flag the 19% increase in admin, which includes investments in the new ERP system. As Michael said, that system is now live, so we expect ERP-related costs to decline in FY 2026 as we settle it in. Because revenue is growing faster than operating expenses and margin is improving, we were able to deliver 95% growth in EBIT versus the prior year, with EBIT reaching AUD 17.8 million in FY 2025. Our net finance income rose 16%, reflecting higher interest earned on our growing cash balance. As a result, profit before tax grew to AUD 22.3 million, up 72% on the prior year. Now, let’s return to gross margin. Our gross profit margin improved 0.3% to 78.2%, helped by the strength of our recurring revenue. It would have been about 78.5% without the tariffs.
I'll offer a few remarks on this. During the fourth quarter of FY 2025, tariffs cost us AUD 0.5 million. That figure might have been larger, though inventory we already had on hand in the U.S. partly offset it. For financial year 2026, the effect of present tariff rates on cost of goods should come to roughly AUD 4 million. We anticipate that will bring the gross margin percentage to somewhere between 75% and 77% in FY 2026, a level beneath what FY 2025 delivered. By pursuing a range of initiatives, among them price increases, we expect to offset most of these tariffs at the EBIT and profit before tax level. Alongside the pricing actions, we will also explore sourcing additional goods from suppliers based in the U.S. and weigh the timing of further OpEx investments. Although these mitigation plans will safeguard profit before tax, pricing actions on their own will not keep the gross margin percentage at FY 2025 levels. Absent these tariffs, our GM for FY 2026 would be expected to land at levels comparable to FY 2025. Turning to OpEx, during FY 2025 our operating expenses as a percentage of revenue declined, with OpEx rising 10% to AUD 138.7 million.
That growth was allocated deliberately. The biggest portion went toward putting money into our main revenue-driving markets so we can keep growing, while 27% was directed into infrastructure and capability—both for now and for what lies ahead. We keep funding R&D to fuel the strategy of expanding our product line. Roughly two-thirds, or AUD 22.3 million, of that R&D spend went to the Endoscope Reprocessing Innovation Program, and AUD 12.5 million went to the Ultrasound Reprocessing Innovation Program. As noted earlier, R&D as a share of revenue declined from 19% to 17%. As I mentioned previously, we anticipate that figure will keep falling in 2026. Through careful allocation of our resources, we're making sure we keep generating growth, innovation, and expansion into new markets, which sets us up for success over the long term. One final note on OpEx: because the government rezoned our current premises in Macquarie Park, we cannot extend the lease past 2027 for our manufacturing and research lab site. Luckily, we secured a site close by under a long-term lease, and it lets us bring our HQ, manufacturing, and research labs together at a single location. We'll start fitting out that site during calendar year 2026, getting ready to move in 2027, when the leases we hold now expire.
That also means, from an accounting standpoint, we'll take on leasing costs for the new property in FY 2026, along with capital expenditure tied to the fit-out in 2026 and 2027. Turning to cash, we had a strong year on that front. Our cash flow has increased thanks to EBIT growth, helped by better accounts receivable collections, reduced inventory holdings, and ongoing growth in service contracts that our customers pay for in advance. That has given us robust cash flow and cash and cash equivalents of AUD 161.6 million, which is a solid foundation for strategic investments down the road. Looking ahead to 2026, we still expect positive cash flow, but it should be lower than 2025 because of rising inventory tied to CORIS commercialization and the costs of fitting out the new property I mentioned earlier. With no debt, we keep full flexibility to allocate capital toward innovation, market expansion, and product development. That puts us in a good position to create long-term shareholder value and drive growth going forward. Now, finally, before I hand back to Michael, let's take a look at the trophon-only business. Here, we show the strength and profitability, which excludes our investments into CORIS. In fiscal year 2025, our trophon-only business continued to demonstrate significant strength and scalability.
Since we already covered revenue and gross profit at the group level, I won't go over that again. For the trophon-only business, operating expenses came in at AUD 108 million, and they grew more slowly than revenue, which was driven by disciplined investments in selling, general, and admin expenses as well as research and development. EBIT for the trophon-only business increased 33% to AUD 48.4 million, which shows positive growth in operating leverage. EBIT represented 24% of sales in FY 2025. On the whole, our trophon-only business keeps generating significant cash flow, and that funds our broader organizational long-term growth strategies. I'll now hand it back to Michael, who will walk you through our growth strategies for the trophon business, give an update on CORIS, and take you through the guidance for 2026.
Thank you so much, Jason. As Jason showed, the standalone trophon business is definitely expanding. It's profitable. It's producing solid cash flow. Importantly, we see five key drivers underpinning sustained growth for this franchise that are outlined on the slide. First of all, you have capital growth. We expect continued growth in both new installed base and upgrades, especially on the back of the launch of our latest generation trophon3. With new installed base in North America, we estimate there's a further approximately 27,000 unit opportunity. That's based on the number of ultrasounds that are in use across that market and, of course, the growth of ultrasound as a clinical modality. We estimate this remaining opportunity to be split roughly 2/3 in the hospital systems and 1/3 in private practices. Interestingly, this split actually mirrors our current sales mix. In our European region, despite a challenging environment, we do still have strong conviction in the overall long-term opportunity there. Overall revenue grew 22% in FY 2025. However, we would have liked to see more new IB come through during the year. With the launch of trophon3, we certainly do have expectations to see stronger new installed base in FY 2026. In APAC, progress in Japan is slow, but there are some encouraging signs coming through.
Additional research has been published that shows pro-contamination, though some studies also demonstrate trophon's effectiveness. The Japanese Society of Stenographers has now put a recommendation into its guidance for HLD that specifically names trophon. We've kept working to get guidelines established across a wider set of societies, and we're heavily engaged with many of the key opinion leaders up there toward that end. In FY 2026, we do intend to launch trophon3 in Japan. On the upgrade side, with roughly 10,000 first-generation trophon EPR units now in the field, the trophon3 launch creates a substantial upgrade opportunity, since customers can effectively skip a generation and move directly from the first generation to the third-generation trophon3, which brings them numerous benefits. The second driver, still tied to capital and in fact a new kind of upgrade, concerns capital software upgrades. This new revenue source will stem from launching the trophon2 Plus software upgrade. For trophon2 users, this software upgrade will in fact deliver the key features of trophon3 on their existing trophon2 machines. That includes a faster cycle time — greater than 40% faster than our current device — plus all the new connectivity features built into the trophon3.
We have roughly 20,000 trophon2 devices out there — in fact, a bit more than that in the market — so this is a significant opportunity over time. To start with, I'd say our emphasis is going to be on the EPR capital upgrades. As we move through the year, we anticipate seeing additional software upgrades come through. The third driver, naturally, is growth in consumables. That comes via core consumables and ecosystem consumables. When I say core, I'm referring to the consumables tied to the disinfection step itself. Growth in that area is fueled by growth in overall ultrasound procedural volume, which we did observe across hospital systems this year, along with the educational work our clinical applications teams do to teach existing customers and trophon users about all the various ultrasound procedures that in fact call for high-level disinfection. Taking those two together, we do expect consumables growth to continue. Growth in the new installed base will be a driver there as well. There's also growth in ecosystem consumables. That consists of the consumables used in the wider reprocessing process. As I noted earlier, that covers items like cleaning and drying wipes and clean probe covers, which are used after the probe has been disinfected, for instance. This year, ecosystem consumables grew 28%, reaching AUD 15 million.
I think there's still a lot of runway for growing this element through raising awareness, through bundling efforts, and through adding new products as well. Our service business is the fourth driver, and in 2025 it grew 21% to AUD 29.4 million. Service has become a meaningful and expanding portion of our business. There's a big opportunity for further upside from ongoing growth in the new installed base, but also considerable upside as we move legacy GE service contracts on those older EPR machines over to Nan through the T3 upgrades that only Nanosonics sells. And finally, the fifth will come on the back of launching T3 and trophon2 Plus, where we have, as I mentioned, enabled integration with DICOM imaging systems. That gives full digital traceability tied to patient records. This sets the stage for growing subscription-based or SaaS-based revenue. In summary, the trophon business really is supported by multiple diverse growth drivers, each an important contributor to strong and sustained growth overall. Moving on from trophon to CORIS, first of all, many important milestones were achieved in the 2025 financial year. There's a clear pathway and plan now in place for broader commercialization. One of the most important achievements was securing the FDA Genova clearance.
That marked an important regulatory achievement, and it now allows us to go after 510(k) filings for indications of broader scope, along with approvals internationally. By expanded scope indications, I mean that scopes come in a great many, many varieties. You have colonoscopes, gastroscopes, bronchoscopes, cystoscopes, and so on. The first Genova clearance relates to colonoscopes. What we intend to do — and CORIS is built for exactly this — is file a sequence of 510(k)s so we gain wide coverage over every type of flexible endoscope, and that will arrive over time. On the operational side, we have laid the groundwork for scale. We have put device manufacturing and the supply chain in place and also established a dedicated consumables production site in the U.S. To build awareness in the market, we have published data and presented at major conferences, highlighting CORIS's superior efficacy outcomes. We have additionally opened regional clinical simulation and education labs in order to engage and train customers. Going forward, the steps are now clearly defined. Our plans are already well advanced for submitting the first 510(k) to the FDA for the first of the expanded scope indications. We are also making progress toward regulatory certification in Europe and Australia. Across this financial year, 2026, we will conduct, as I said earlier, a controlled market release of CORIS.
The rollout will begin in Europe and Australia first, and then in the U.S. once we receive approval of the initial 510(k) for the expanded scope indications. As many of you know, when you're effectively introducing a new-to-world technology that we believe can truly transform endoscope reprocessing, a controlled market release matters a great deal. It entails a strategically limited launch into chosen user settings for full commercialization. This allows for real-world feedback and helps us spot and address any unforeseen problems before we go to broad commercialization. Much is to be accomplished in FY 2026. Still, through these measured steps, we're making sure CORIS is certainly positioned for long-term success. We all anticipate, and we believe, that a significant growth opportunity exists with CORIS. More than 60 million flexible endoscope procedures take place each year, and that's only across the top seven key markets by themselves. CORIS does represent a substantial growth opportunity for the organization. Similar, I guess, to the trophon business, our business model for CORIS is certainly built to draw on multiple revenue streams to ensure a robust and scalable approach. Importantly, while the overall capital unit opportunity may be somewhat lower than trophon, and that's because they're all centralized in the endoscope reprocessing suites, whereas with trophon, they're actually there in the clinical setting at point of care.
Since these systems are centralized, we expect recurring revenue per device from consumables to be much higher than with trophon, and that comes from how many cycles each machine runs every day. The reason is that every endoscope has to be reprocessed. On top of that, the price for each cycle will be higher as well, given that manual cleaning today costs somewhere in the $11 to $37 range. That is truly a meaningful opportunity, particularly when it comes to consumables. Lastly, let me turn to our guidance for this financial year. As we said in the ASX release, we feel we are strongly placed to keep gaining from a number of health care trends, and infection prevention in particular, including the shift toward automation, traceability requirements, and growing digitalization. Naturally, the opportunities from our recently launched trophon3 and trophon2 Plus will drive that. Like any company, I suppose, we are taking a cautious stance given macroeconomic uncertainty and acknowledging the shifting global trade landscape. Against that background, looking toward FY 2026, we expect revenue to keep growing, with total revenue in the range of AUD 215 million-AUD 223 million. That works out to 8%-12% growth. This growth takes in continuing capital revenue growth fueled by the recent launches, as well as ongoing recurring revenue growth stemming from our customer value expansion strategies.
As I've mentioned previously, I should note that we expect minimal revenue in FY 2026 for CORIS from the controlled market release. The bulk of that revenue growth is certainly tied to trophon. Per Jason's explanation, we anticipate a gross margin ranging from 75% to 77%, factoring in tariff effects which, as he noted, will come to roughly AUD 4 million on the cost of goods line. Absent those tariffs, our expectation would have been for gross margin to remain comparable to FY 2025, above 78%. That said, we have a number of mitigation strategies underway designed to offset most of this hit at the profit before tax line. Among these are cost-sharing initiatives, meaning price increases will occur. We need to ensure those adjustments remain reasonable over time. Additionally, our efforts around various sourcing strategies inside the U.S. aim to blunt the tariff impacts to the greatest extent feasible. Turning to operating expenses, we again expect them to increase at a slower pace than revenue, with OpEx growth projected in the 6%-9% range for the year. To sum up, FY 2025, I'd say, was a year marked by numerous financial and operational accomplishments.
We feel sure we can produce a further strong year in FY 2026. So with that, I'll pass things back to the operator now so we can begin the Q&A. Thank you.
Thanks. If you'd like to ask a question, hit star one on your phone and hang on until your name is called. To cancel your request, press star two. Should you be on a speakerphone, kindly lift the handset before posing your question. Our first question this session is from Shane Storey at Wilsons Advisory. The line is yours.
Good morning, everyone. Michael, I’d like to begin with the guidance, please—really just seeking clarification more than anything else. Regarding the revenue guidance you provided, I assume it incorporates some of those price increases you’re considering as part of a mitigation strategy against the tariffs. When we work through the guidance across the various lines and arrive at an EBIT figure, that EBIT figure will still reflect that price increase, if that makes sense.
Yes, as far as pricing goes, any adjustments we implement over the course of the year are already factored into the revenue guidance we've given for the top line.
All right. So if I look at what drives that AUD 8 million gap, I suppose, from the low end of guidance to the high end, am I right to think the low end would basically mean a fairly flat capital result in 2026, while the high end might assume somewhat more activity?
That's exactly right. Obviously, we've provided ranges. With trophon3 and trophon2 Plus coming to market, we see a strong chance to keep growing unit volumes. Shane, it also factors in somewhat the possibility of structural shifts—which we aren't really expecting in the U.S.—just in case hospitals face greater budgetary pressure, which again, we aren't really encountering right now. Should any structural changes push things toward rentals or similar arrangements, we'd still get the units, but we wouldn't receive all the revenue upfront. On the bottom line, the way you're framing it is precisely correct. At the low end of the guidance, that would correspond to flat capital growth.
Appreciate it — that covers everything on my end. Thank you.
Appreciate it.
Thanks. Our following question is from Josh Kannourakis of Barrenjoey. You have the floor.
Hi, Michael and Jason. I’ve just got a couple of quick questions. First, on guidance as well: could we just go through the OpEx side, and can you give us maybe a bit of extra context around how we should be thinking about depreciation into next year? Also, maybe just a little bit more around some of the rental costs and other potential one-offs that are sort of coming through in 2026?
Absolutely, Josh, happy to handle that question. We anticipate depreciation will come in higher—roughly AUD 2 million above FY 2025—driven by the fit-out of the CORIS manufacturing line ahead of the go-live, as you'd expect. There's also depreciation tied to the U.S. manufacturing setup for the Sonics and CORIS consumable. So about AUD 2 million of extra depreciation in 2026. As for the new property, we should get access around April 2026, and at that point accounting rules will require us to recognize some lease-related costs—approximately AUD 600,000 to AUD 700,000 in additional leasing costs during the 2026 year. We'll also have CapEx related to fitting out that property across 2026 and 2027. My estimate is somewhere between AUD 10 million and AUD 12 million over those two years, so AUD 10 million to AUD 12 million in total. That will then depreciate across the lease term, which runs 10 years. A few new items there.
Understood. Jason, regarding capital expenditures, how should we think about the wider business CapEx profile through 2026?
So in 2025, our spend came to just about AUD 9 million. For 2026, my expectation is roughly AUD 10 million. Of that, half relates to fitting out the new building, and the remaining AUD 4 million or AUD 5 million is essentially a return to a typical CapEx run rate for the business. That's about what I'd expect.
Thanks. Michael, a quick question about CORIS. We’ve obviously discussed the higher cycles per machine. Compared with trophon as well, it seems the cycles there have been rising too. Could you give us some sense of what you’re seeing in terms of how daily cycles across the portfolio are trending, both for trophon and what that means for CORIS cycles as well?
Yeah, I believe that's on trophon, and the cycles average out across the 37,000. Clearly we're seeing some modest improvement, and that's really coming more from procedural volumes rising in ultrasound overall. It's tough to compare trophon with CORIS since the two are completely different things, obviously. The way to think about it is that in ultrasound, not every ultrasound procedure calls for high-level disinfection. Where a trophon sits in a clinical setting, they might perform 15 or more ultrasound procedures in a day, yet only three or four of those need high-level disinfection. In endoscopy, by contrast, every single one does. Where a CORIS is actually installed in an endoscopy reprocessing suite, every endoscope that arrives has to be reprocessed. You could see threefold plus the number of cycles running through a CORIS device compared with a trophon device. While we haven't yet disclosed to the market the price per cycle or the consumable, you know the lower-end cost of doing this cleaning manually today runs around AUD 10. We think there's substantial opportunity there for that consumable revenue to come through with CORIS.
Understood — that helps. One last question from me, going back to some of the upgrades, particularly the capital software upgrades. How should we think about the possible revenue uplift from upgrading the existing trophon2s from a software standpoint?
Right. Like I said at the start, the software has to get loaded onto the machine, which lets them hook up their devices, and we can attempt the software download, though field engineers will be needed to assist with the upgrade at the outset. At first we'll be heavily concentrated on the EPR upgrades — the straightforward capital upgrades coming from EPR T3. We aren't viewing this as, or pushing it to be, a highlight, and definitely not in the first half. We expect growth here to show up in the second half. As for certain customers we sold T2s to right at the end of the last financial year, clearly we went in and upgraded those as part of what they bought. I can say that the feedback we've gotten from those customers about the upgrade has been extremely positive.
All right, that's good. Let's hand it over to someone else. Appreciate it, Gus.
Thank you. As a reminder, if you'd like to pose a question, simply hit star one on your phone and hold until your name is called. Our next question is from Elyse Shapiro at Canaccord Genuity. The line is yours.
Hey, guys. Thanks for taking the question. Kind of continuing along that software thread, when we think about the yearly, I suppose, annuity stream for each device, is there also a SaaS element tied to the DICOM compatibility piece, on top of what the initial software upgrades cost?
Yes, upgrading will involve an upfront expense, and after that we anticipate a yearly subscription fee for cloud-based DICOM connectivity. That would likely come to roughly — let’s round it — around AUD 1,000 each year.
All right, that helps a lot. Regarding CORIS, I'd say expectations for FY 2026 are fairly minimal. Could you share some color and feedback on any early demand you're seeing, how discussions with hospitals have been progressing, and roughly what the timing looks like for some of those first sites? Thanks.
Right. Of course, we haven't started actively pursuing orders at this point, but a great deal of education has been underway. Many people have come through the clinical simulation labs. What I can tell you is that the customers who are visiting clearly grasp the need and the issues that exist with how cleaning is currently done. You only have to look, and you'll find it in the investor presentation. Adverse events are rising, and most of those rising adverse events are tied to contamination risks. That's because these channels are still contaminated, particularly the ones that can't be brushed, while CORIS handles every one of them. They're very impressed by the technology, by what it does, and by the results it delivers. What we want to do, and what we're highly focused on right now, is reaching this controlled market release, learning from it, and I think that will give us some really good indications about what the demand profile may begin to look like in FY 2027.
Thanks, that's useful. Just one final question. In the past, you've tended to keep an open mind about possible M&A that could bring in new product lines. Does that remain something you're considering?
Well, we remain extremely open-minded on this front. Cash generation for the year came in at roughly AUD 32 million, as Jason mentioned, which is close to twice the prior year's figure. That has left us with a cash balance of AUD 161 million on the balance sheet. It's a nice problem to have, in a way, but we want to deploy that capital as effectively as we can for shareholders. On M&A, we're still looking, provided we can find a deal that makes sense. So far we've reviewed a range of options, but none have proven sensible. What I do anticipate, though, is that CORIS will open up additional opportunities for us to examine, since the value stream—viewed from the endoscope's perspective, from the moment it's used until it's ready for use again—what occurs across that entire reprocessing value stream involves many elements. Much as we've established an ecosystem around our trophon business, I believe M&A could give us chances to build a solid ecosystem of products around CORIS too. My sense is CORIS may open that door for us.
Naturally, we don’t want the dog being wagged by its tail. CORIS would be brought out by us first.
Excellent — I appreciate that, and it’s useful.
Thank you. Our following question is from Taj Wesson of RBC. Kindly proceed.
Good morning, everyone. Appreciate you fielding my question. What I'm focused on is U.S. hospital CapEx budgets and the gradual tightening observed across roughly the past 6 to 12 months. I'd like to get a sense of how many of your customers might fit with those remarks. And second, is that factored into the 2026 guidance?
Those capital budget limitations we were observing roughly more than a year back—we aren't really encountering them now. Hospitals, clearly, remain quite careful when it comes to spending on capital. Looking even at the numbers you're seeing during this year—close to 4,000 units sold in total—at this point we aren't running into significant kinds of disruptions tied to hospital capital budgets. That doesn't mean they won't appear. There are plenty of shifts with new legislation moving through in the U.S., the big beautiful bill, along with Medicare and Medicaid changes, and so on. At this stage we aren't observing shifts in patient volumes at hospitals. We did see that with our consumables. Should we be, should we find ourselves up against hospital capital budgets, at least when it comes to the trophon business and in fact even with CORIS, we're positioned very strongly to provide a variety of models. As I mentioned, those could be rentals, which increased slightly last year. We have other kinds of products, such as own-it-through service. We recognize the revenue on those. There may have been around AUD 200,000 in the past 12 months. We recognize the revenue. We do have optionalities available to assist our customers if capital budget constraints do arise.
That's a fair point. We need to keep that in mind. Our guidance already factors that in.
Thanks. On Trophon specifically, you gave the EBIT margin for that business. As new products come online and penetration rises, could you offer some color on what margin potential looks like for that unit?
So regarding trophon, I think we'd still like to see additional leverage come through and EBIT margins get a bit better yet. At this point, 24% is a fairly solid margin. As for CORIS, the business model will be precisely the same. In reality, it will likely skew more toward consumables. Once we reach the appropriate degree of market penetration with CORIS — which is going to take some time — once that penetration is achieved, we do think EBIT margins for a business such as CORIS could be somewhat better still.
Perfect. Thanks. That covers everything on my end.
I appreciate that.
Thanks. The following question is from John Hester at Bell Potter. Go right ahead.
Hello there, Michael and Jason.
Hi there, John.
Michael, regarding your R&D spend, in FY 2025 you're putting 21% or 17% of revenue into R&D. Could you walk us through roughly how much of that is internal versus external? It looks like several of your projects have reached a logical conclusion, more or less. What comes next for your R&D budget?
Most of it is entirely in-house. What you're seeing for R&D there is, well, that's the statutory R&D reporting, and it takes in quite a lot. It covers all our biosciences work, clinical, everything of that kind. Engineering isn't the only piece. We do say certain items reach a natural end point. My view is that with a medical device, nothing really ends, since new generations will keep coming. Software upgrades will keep coming as well. And as we keep advancing with our scope, broader indications and so on, I think we'll still be putting money into our CORIS R&D going forward, at least for a while. Yes, how the split looks between what goes to CORIS, what goes to trophon, and what goes to something new — that could all shift. The broad point I'd make is that we remain committed to innovation from within on an ongoing basis. We're equally committed to R&D, measured as a percentage of revenue, continuing to come down.
If we're talking about absolute figures?
I won't be providing a number at this point. In the same way that it dropped from 19% to 17%, it could decline once more by roughly another 2 points or so in the coming year. We'll see.
That's fair. On the CORIS device specifically, have you thought at all yet about how you'll set the price compared with the $11 to $37 estimated reprocessing cost that exists today? What I'm driving at is this: do you expect to run into pushback from hospitals about absorbing an extra cost on top of what they already pay for reprocessing?
Yeah, I think there are a lot of costs involved. Obviously, the purely financial cost is one. The short answer is yes, we've factored that in. We're examining the full economics of it. We just haven't disclosed that to the market yet. That $11-$37 figure simply gives people a sense of the opportunity that exists. Plenty of costs are baked into what hospitals absorb. It isn't only the time cost, you know, the user cost. It's the cost of absences. There's a great deal in it, John. We believe the price point we're going to set it at will be an accessible one. We've conducted research to actually confirm that. Some of that will emerge as we bring it out to market a bit more broadly.
Alright, thanks a lot.
Thanks. At this point we don’t have any more questions. I’ll hand the conference back now for any closing remarks.
Thanks once more, everyone, for being on the call. To recap what I mentioned, we feel FY 2025 was truly an excellent year for the company, in both financial and operational terms, and it has positioned us to hopefully produce another strong outcome for you in FY 2026. I'm certain I'll be talking with many of you in the days ahead. Thanks to all of you for taking part.
That brings today's conference to a close. We appreciate everyone joining us. You're welcome to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nanosonics Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Nanosonics Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.